The effect of luseogliflozin on liver fibrosis differs depending on alcohol consumption in patients with type 2 diabetes

Association between the effect of luseogliflozin on liver fibrosis and alcohol consumption - Association between the effect of luseogliflozin on liver fibrosis and alcohol consumption

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055384

Enrollment

200

Registered

2024-08-31

Start date

2014-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes whose drinking habits were known and who continued luseogliflozin therapy over 12 months

Exclusion criteria

Exclusion criteria: Subjects whose observation period was less than 12 months Subjects whose drinking habits were unknown

Design outcomes

Primary

Measure	Time frame
FIB-4	—

Secondary

Measure	Time frame
HbA1c, body weight, and serum albumin concentration	—

Countries

Japan

Contacts

Public ContactHiroyuki Ito

Edogawa Hospital Department of Diabetes, Metabolism and Kidney Disease

ito@edogawa.or.jp03-3673-1221

Outcome results